Dr. Wang-Gillam Discusses the NAPOLI-1 Trial in Pancreatic Cancer

Andrea Wang-Gillam, MD, PhD
Published: Saturday, Jun 28, 2014

Andrea Wang-Gillam, MD, PhD, assistant professor, Department of Medicine, Oncology Division, Washington University School of Medicine and Siteman Cancer Center in St. Louis, discusses the trial design and results of the phase III NAPOLI-1 trial that examined MM-398 with 5-fluorouracil (5-FU) and leucovorin in patients with metastatic pancreatic cancer following progression on gemcitabine-based therapy.

Wang-Gillam says the primary endpoint of the study was overall survival (OS) and secondary endpoints included progression-free survival and response rate. The study was done globally and recruited patients from over 100 sites. The study had 3 arms, one examining MM-398 monotherapy, the second looking at 5-FU with leucovorin (control), and the third examined the combination of MM-398, 5-FU, and leucovorin.

Results of the study showed that the combination arm of MM-398 plus 5-FU/leucovorin had a superior OS compared with 5-FU/leucovorin alone (OS = 6.1 months vs 4.2 months). The combination of MM-398 plus 5-FU/leucovorin also showed superior progression-free survival (PFS), overall response rare (ORR), and CA19-9 response. 

The median PFS was 3.1 months for the combination compared with 1.5 months with the control (HR = 0.56; 95% CI, 0.41-0.75; P = .0001). The ORR was 16% versus 1% (P <.001) and CA19-9 levels were decreased by ≥50% in 36% versus 12% of patients in the combination and control arms, respectively.

<<< View more from the 2014 World GI Congress

Andrea Wang-Gillam, MD, PhD, assistant professor, Department of Medicine, Oncology Division, Washington University School of Medicine and Siteman Cancer Center in St. Louis, discusses the trial design and results of the phase III NAPOLI-1 trial that examined MM-398 with 5-fluorouracil (5-FU) and leucovorin in patients with metastatic pancreatic cancer following progression on gemcitabine-based therapy.

Wang-Gillam says the primary endpoint of the study was overall survival (OS) and secondary endpoints included progression-free survival and response rate. The study was done globally and recruited patients from over 100 sites. The study had 3 arms, one examining MM-398 monotherapy, the second looking at 5-FU with leucovorin (control), and the third examined the combination of MM-398, 5-FU, and leucovorin.

Results of the study showed that the combination arm of MM-398 plus 5-FU/leucovorin had a superior OS compared with 5-FU/leucovorin alone (OS = 6.1 months vs 4.2 months). The combination of MM-398 plus 5-FU/leucovorin also showed superior progression-free survival (PFS), overall response rare (ORR), and CA19-9 response. 

The median PFS was 3.1 months for the combination compared with 1.5 months with the control (HR = 0.56; 95% CI, 0.41-0.75; P = .0001). The ORR was 16% versus 1% (P <.001) and CA19-9 levels were decreased by ≥50% in 36% versus 12% of patients in the combination and control arms, respectively.

<<< View more from the 2014 World GI Congress




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Integrating Novel Targeted Treatment Strategies to Advance Pancreatic Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x